About Us
EVDL is a Hong Kong homegrown start-up formed by medical doctors, experienced scientists and engineers having the vision and passion in providing solutions to unmet medical needs. With a unique integration of expertise of our multidisciplinary professionals, from scientific research to manufacturing, we are able to transfer knowledge to innovative yet practical diagnostic solutions to the community. As part of the Avalon Biomedical (Management) Limited, a local biotechnology incubator, we aspire to become a worldwide leader in diagnostic industry and to push Diagnosis beyond Boundaries!
EVDL is a Hong Kong homegrown start-up formed by medical doctors, experienced scientists and engineers having the vision and passion in providing solutions to unmet medical needs. With a unique integration of expertise of our multidisciplinary professionals, from scientific research to manufacturing, we are able to transfer knowledge to innovative yet practical diagnostic solutions to the community. As part of the Avalon Biomedical (Management) Limited, a local biotechnology incubator, we aspire to become a worldwide leader in diagnostic industry and to push Diagnosis beyond Boundaries!
What We Do
State-of-the-art Solution for Unmet Medical Need
The emergence of novel infectious diseases causing potential pandemic are continuously posing worldwide threats throughout history. From Asian Flu to Avian Flu, and from Swine Flu and various Coronaviruses, the market has long been lacking an all-in-one, comprehensive diagnostic system that is both effective and efficient in many ways.
Prompt and accurate diagnosis is the first step for successful control of potential epidemics. Not only should the system ideally be fast, accurate and easy to operate from sample to result, but also multiplexing and low cost which is affordable by all. EVDL has now a total solution to this unmet medical need.
What We Do
State-of-the-art Solution for Unmet Medical Need
The emergence of novel infectious diseases causing potential pandemic are continuously posing worldwide threats throughout history. From Asian Flu to Avian Flu, and from Swine Flu and various Coronaviruses, the market has long been lacking an all-in-one, comprehensive diagnostic system that is both effective and efficient in many ways.
Prompt and accurate diagnosis is the first step for successful control of potential epidemics. Not only should the system ideally be fast, accurate and easy to operate from sample to result, but also multiplexing and low cost which is affordable by all. EVDL has now a total solution to this unmet medical need.
Milestone
2015
Project Start &
Design Phase
July
Emerging Viral Diagnostics (HK) Limited (“EVDL”) was founded
The core research team is formed by famous scientists, doctors, experienced biotechnologists and engineers as well as technical and technology investors.
Nov
Establishment of Respiratory Virus Research Foundation
HKU and PolyU jointly announced the establishment of “Respiratory Virus Research Foundation”. EVDL and the research team from the Universities immediately kickstarted related virus and translational research work.
July
Emerging Viral Diagnostics (HK) Limited (“EVDL”) was founded
The core research team is formed by famous scientists, doctors, experienced biotechnologists and engineers as well as technical and technology investors.
Nov
Establishment of Respiratory Virus Research Foundation
HKU and PolyU jointly announced the establishment of “Respiratory Virus Research Foundation”. EVDL and the research team from the Universities immediately kickstarted related virus and translational research work.
2018
Establishment of Prototype Machine &
Biochemistry Reagents
Dec
Successfully Detected Samples
Successful detection of clinical samples in Queen Mary Hospital (QMH). Design of prototype machine and biochemistry reagents established and with more optimization work in the pipeline.
Dec
Successfully Detected Samples
Successful detection of clinical samples in Queen Mary Hospital (QMH). Design of prototype machine and biochemistry reagents established and with more optimization work in the pipeline.
2020
First Introduction of the EVDL System to the Public
JAN
Demonstrated the strength as Platform Technology during outbreak of COVID-19
The research team promptly adapted the system and successfully detected SARS-CoV-2 clinical samples during the outbreak of COVID-19 in late 2019. Followed by a Press Conference held in PolyU announcing the technology to public in February.
JAN
Demonstrated the strength as Platform Technology during outbreak of COVID-19
The research team promptly adapted the system and successfully detected SARS-CoV-2 clinical samples during the outbreak of COVID-19 in late 2019. Followed by a Press Conference held in PolyU announcing the technology to public in February.
2021
Technology Transfer from University Scale to Industrial Scale
Jan
First Production Site in PingShan, Shenzhen
Under a collaboration framework agreement with the People’s Government of Pingshan District, Shenzhen, Guangdong Province, China and Xiangxue Pharmaceutical, a factory site is established in PingShan, Shenzhen.
JUL
First Production Site in Hong Kong
EVDL celebrates its first production site with a focus on the device. This site will also act as engineering workshop and main hub for device's R&D work.
Jan
First Production Site in PingShan, Shenzhen
Under a collaboration framework agreement with the People’s Government of Pingshan District, Shenzhen, Guangdong Province, China and Xiangxue Pharmaceutical, a factory site is established in PingShan, Shenzhen.
JUL
First Production Site in Hong Kong
EVDL celebrates its first production site with a focus on the device. This site will also act as engineering workshop and main hub for device's R&D work.
2022
A Leap Forward to Further Expansion and Certification
JUN
Device Production Site in Hong Kong is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
AUG
Signing Ceremony of Strategic Partnership and Opening Ceremony of Production Site in MARS Centre, Hong Kong
EVDL enters into strategic partnership with Shenzhou Space Biotechnology Group (“SBG”) and takes a step forward to clinical trials and product registration. The Company also celebrates the opening of its reagent and microfluidic cartridge production site
Dec
Cartridge Production Site in Hong Kong is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
JUN
Device Production Site in Hong Kong is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
AUG
Signing Ceremony of Strategic Partnership and Opening Ceremony of Production Site in MARS Centre, Hong Kong
EVDL enters into strategic partnership with Shenzhou Space Biotechnology Group (“SBG”) and takes a step forward to clinical trials and product registration. The Company also celebrates the opening of its reagent and microfluidic cartridge production site
Dec
Cartridge Production Site in Hong Kong is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
2023
Soft Launch
Jan-Dec
Initial Deployment in Different Markets in the Greater Bay Area for Practical Operations
AAMST is now in service at different clinics, private hospitals, laboratories, and more in the Greater Bay Area
Mar
Pingshan, Shenzhen Government and Avalon Group have reached a strategic cooperation intention
Pingshan, Shenzhen Government and Avalon Group will settle the independent research and development project "Avalon Automated Multiplex System" in Pingshan, Shenzhen
Jan-Dec
Initial Deployment in Different Markets in the Greater Bay Area for Practical Operations
AAMST is now in service at different clinics, private hospitals, laboratories, and more in the Greater Bay Area
Mar
Pingshan, Shenzhen Government and Avalon Group have reached a strategic cooperation intention
Pingshan, Shenzhen Government and Avalon Group will settle the independent research and development project "Avalon Automated Multiplex System" in Pingshan, Shenzhen
2024
Jan
Recognition as the sole Hong Kong awardee of the esteemed "2023 Deloitte China Life Sciences & Healthcare Rising Star" accolade.
This prestigious recognition underscores EVDL's commitment to providing innovative solutions to unmet medical needs.
Apr
Honored with “HKIE MIS Industry Award 2023 - New Industrialization Gold Award”
This recognition is a testament to EVDL's outstanding achievements in the engineering field, further affirming their exceptional performance in enhancing productivity, product quality, and innovation.
May
Cartridge Production Site in PingShan, China is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
May
Receives support from RAISe+ Scheme by ITC of HKSAR, EVDL and HKBU join hands to promote HKSAR I&T Ecosystem
This recognition affirms AAMST's strengths in terms of I&T component, commercial viability, relevance with government policies and the overall interest of the community.
July
EVDL is proud to have AAMST in the “World Health Organization (WHO) Compendium of Innovative Health Technologies for Low-Resource Settings 2024”
Jan
Recognition as the sole Hong Kong awardee of the esteemed "2023 Deloitte China Life Sciences & Healthcare Rising Star" accolade.
This prestigious recognition underscores EVDL's commitment to providing innovative solutions to unmet medical needs.
Apr
Honored with “HKIE MIS Industry Award 2023 - New Industrialization Gold Award”
This recognition is a testament to EVDL's outstanding achievements in the engineering field, further affirming their exceptional performance in enhancing productivity, product quality, and innovation.
May
Cartridge Production Site in PingShan, China is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
May
Receives support from RAISe+ Scheme by ITC of HKSAR, EVDL and HKBU join hands to promote HKSAR I&T Ecosystem
This recognition affirms AAMST's strengths in terms of I&T component, commercial viability, relevance with government policies and the overall interest of the community.
July
EVDL is proud to have AAMST in the “World Health Organization (WHO) Compendium of Innovative Health Technologies for Low-Resource Settings 2024”
Milestone
2015
Project Start &
Design Phase
July
Emerging Viral Diagnostics (HK) Limited (“EVDL”) was founded
The core research team is formed by famous scientists, doctors, experienced biotechnologists and engineers as well as technical and technology investors.
July
Emerging Viral Diagnostics (HK) Limited (“EVDL”) was founded
The core research team is formed by famous scientists, doctors, experienced biotechnologists and engineers as well as technical and technology investors.
Nov
Establishment of Respiratory Virus Research Foundation
HKU and PolyU jointly announced the establishment of “Respiratory Virus Research Foundation”. EVDL and the research team from the Universities immediately kickstarted related virus and translational research work.
Nov
Establishment of Respiratory Virus Research Foundation
HKU and PolyU jointly announced the establishment of “Respiratory Virus Research Foundation”. EVDL and the research team from the Universities immediately kickstarted related virus and translational research work.
2018
Establishment of Prototype Machine &
Biochemistry Reagents
Dec
Successfully Detected Samples
Successful detection of clinical samples in Queen Mary Hospital (QMH). Design of prototype machine and biochemistry reagents established and with more optimization work in the pipeline.
Dec
Successfully Detected Samples
Successful detection of clinical samples in Queen Mary Hospital (QMH). Design of prototype machine and biochemistry reagents established and with more optimization work in the pipeline.
2020
First Introduction of the EVDL System to the Public
JAN
Demonstrated the strength as Platform Technology during outbreak of COVID-19
The research team promptly adapted the system and successfully detected SARS-CoV-2 clinical samples during the outbreak of COVID-19 in late 2019. Followed by a Press Conference held in PolyU announcing the technology to public in February.
JAN
Demonstrated the strength as Platform Technology during outbreak of COVID-19
The research team promptly adapted the system and successfully detected SARS-CoV-2 clinical samples during the outbreak of COVID-19 in late 2019. Followed by a Press Conference held in PolyU announcing the technology to public in February.
2021
Technology Transfer from University Scale to Industrial Scale
Jan
First Production Site in PingShan, Shenzhen
Under a collaboration framework agreement with the People’s Government of Pingshan District, Shenzhen, Guangdong Province, China and Xiangxue Pharmaceutical, a factory site is established in PingShan, Shenzhen.
Jan
First Production Site in PingShan, Shenzhen
Under a collaboration framework agreement with the People’s Government of Pingshan District, Shenzhen, Guangdong Province, China and Xiangxue Pharmaceutical, a factory site is established in PingShan, Shenzhen.
JUL
First Production Site in Hong Kong
EVDL celebrates its first production site with a focus on the device. This site will also act as engineering workshop and main hub for device's R&D work.
JUL
First Production Site in Hong Kong
EVDL celebrates its first production site with a focus on the device. This site will also act as engineering workshop and main hub for device's R&D work.
2022
A Leap Forward to Further Expansion and Certification
JUN
Device Production Site in Hong Kong is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
JUN
Device Production Site in Hong Kong is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
AUG
Signing Ceremony of Strategic Partnership and Opening Ceremony of Production Site in MARS Centre, Hong Kong
EVDL enters into strategic partnership with Shenzhou Space Biotechnology Group (“SBG”) and takes a step forward to clinical trials and product registration. The Company also celebrates the opening of its reagent and microfluidic cartridge production site
AUG
Signing Ceremony of Strategic Partnership and Opening Ceremony of Production Site in MARS Centre, Hong Kong
EVDL enters into strategic partnership with Shenzhou Space Biotechnology Group (“SBG”) and takes a step forward to clinical trials and product registration. The Company also celebrates the opening of its reagent and microfluidic cartridge production site
Dec
Cartridge Production Site in Hong Kong is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
Dec
Cartridge Production Site in Hong Kong is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
2023
Soft Launch
Jan-Dec
Initial Deployment in Different Markets in the Greater Bay Area for Practical Operations
AAMST is now in service at different clinics, private hospitals, laboratories, and more in the Greater Bay Area
Jan-Dec
Initial Deployment in Different Markets in the Greater Bay Area for Practical Operations
AAMST is now in service at different clinics, private hospitals, laboratories, and more in the Greater Bay Area
Mar
Pingshan, Shenzhen Government and Avalon Group have reached a strategic cooperation intention
Pingshan, Shenzhen Government and Avalon Group will settle the independent research and development project "Avalon Automated Multiplex System" in Pingshan, Shenzhen
Mar
Pingshan, Shenzhen Government and Avalon Group have reached a strategic cooperation intention
Pingshan, Shenzhen Government and Avalon Group will settle the independent research and development project "Avalon Automated Multiplex System" in Pingshan, Shenzhen
2024
Jan
Recognition as the sole Hong Kong awardee of the esteemed "2023 Deloitte China Life Sciences & Healthcare Rising Star" accolade.
This prestigious recognition underscores EVDL's commitment to providing innovative solutions to unmet medical needs.
Jan
Recognition as the sole Hong Kong awardee of the esteemed "2023 Deloitte China Life Sciences & Healthcare Rising Star" accolade.
This prestigious recognition underscores EVDL's commitment to providing innovative solutions to unmet medical needs.
Apr
Honored with “HKIE MIS Industry Award 2023 - New Industrialization Gold Award”
This recognition is a testament to EVDL's outstanding achievements in the engineering field, further affirming their exceptional performance in enhancing productivity, product quality, and innovation.
Apr
Honored with “HKIE MIS Industry Award 2023 - New Industrialization Gold Award”
This recognition is a testament to EVDL's outstanding achievements in the engineering field, further affirming their exceptional performance in enhancing productivity, product quality, and innovation.
May
Cartridge Production Site in PingShan, China is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
May
Cartridge Production Site in PingShan, China is ISO 13485:2016 Certified
Proud to announce the site is ISO 13485:2016 certified and in compliance with international quality management standard for medical device.
May
Receives support from RAISe+ Scheme by ITC of HKSAR, EVDL and HKBU join hands to promote HKSAR I&T Ecosystem
This recognition affirms AAMST's strengths in terms of I&T component, commercial viability, relevance with government policies and the overall interest of the community.
May
Receives support from RAISe+ Scheme by ITC of HKSAR, EVDL and HKBU join hands to promote HKSAR I&T Ecosystem
This recognition affirms AAMST's strengths in terms of I&T component, commercial viability, relevance with government policies and the overall interest of the community.
July
EVDL is proud to have AAMST in the “World Health Organization (WHO) Compendium of Innovative Health Technologies for Low-Resource Settings 2024”
July
EVDL is proud to have AAMST in the “World Health Organization (WHO) Compendium of Innovative Health Technologies for Low-Resource Settings 2024”
